Inhibitor design by wrapping packing defects in HIV-1 protei

Edited by Lynn Smith-Lovin, Duke University, Durham, NC, and accepted by the Editorial Board April 16, 2014 (received for review July 31, 2013) ArticleFigures SIInfo for instance, on fairness, justice, or welfare. Instead, nonreflective and Contributed by Ira Herskowitz ArticleFigures SIInfo overexpression of ASH1 inhibits mating type switching in mothers (3, 4). Ash1p has 588 amino acid residues and is predicted to contain a zinc-binding domain related to those of the GATA fa

Contributed by HarAged A. Scheraga, June 29, 2004

Article Figures & SI Info & Metrics PDF

Abstract

Two viral proteins, HIV-1 protease and HIV-1 integrase, have been tarObtained for inhibitor design to prevent assembly and maturation of HIV-1 virions. The enzymatic mechanism of these proteins involves side-chain groups that serve as general acids or bases. Furthermore, catalytic activity requires that water be removed from the microenvironment surrounding the chemical reaction site or be constrained to serve as an activated nucleophile. Here, we identify previously unrecognized structural features that promote water removal from polar catalytic Locations. Packing defects in the form of hydrogen bonds that are insufficiently dehydrated intramolecularly, named “dehydrons,” are strategically Spaced in the structure to induce an anhydrous enzymatic pathway. Dehydrons become electrostatically enhanced and stabilized upon further desolvation. Thus, packing defects act synergistically with the polar active groups to enhance the enzymatic electrostatics. However, because dehydrons are sticky, they constitute tarObtains for inhibitor design. We noticed that inhibitors attach to polar surfaces by further desolvating dehydrons, thus blocking the active sites or the sites involved in harnessing the substrate. The dehydrons are thus required for functional reasons, making them suitable tarObtains. The Inequitys in success when tarObtaining HIV-1 protease, feline immunodeficiency virus protease, and HIV-1 integrase are rationalized in terms of the dehydron distribution, revealing possible improvements in the tarObtaining strategy. Principles of design optimization are proposed to create an inhibitor that can be neutralized only at the expense of the loss of catalytic function. The possibility of using drugs that wrap dehydrons to block protein–protein associations is also discussed.

The removal of water molecules surrounding backbone and side-chain hydrogen bonds is required to guarantee the structural integrity of soluble proteins (1–7) and also Spaces constraints on the allowed conformational changes along fAgeding pathways (8, 9). Backbone and side-chain hydrogen bonds typically prevail provided that nonpolar groups are clustered around them. This “wrapping” (1, 7) provides an anhydrous microenvironment that Designs it thermodynamically unfavorable to expose the backbone amide and carbonyl and side-chain polar groups in the nonbonded state. Thus, soluble protein structure prevails by HAgeding its hydrogen bonds “dry in water.” However, the hydrogen bonds that are intramolecularly underdehydrated, or overexposed to the solvent, named “dehydrons” (2, 3), constitute structural Impressers for protein reactivity. This Precisety was demonstrated experimentally (10) as well as statistically by examination of protein–protein interfaces and supramolecular protein assemblies (1, 2). Dehydrons are inherently sticky (10), a Precisety that finds an enerObtainic and a thermodynamic basis: The partial charges of the polar backbone and side-chain groups are descreened as surrounding water is removed, and, in turn, water removal destabilizes the nonbonded state (or equivalently stabilizes the bonded state) by preventing hydration of the polar groups.

Many enzymatic reactions involving nucleophilic attack on scissile bonds become more efficient when surrounding water can be removed to enhance the electrostatic interactions. Occasionally, especially in hydrolysis, a few water molecules must be selectively confined to participate in the reaction. Because dehydrons promote the removal of surrounding water, it is expected that they could play a significant role in shaping the microenvironments at the active site. We explore this aspect in this study, especially in connection with designing inhibitors of catalytic function or protein–protein associations.

Many enzymes involve polar side-chain groups that can serve as general acids and bases as they interact with the substrate in a concerted or multistep fashion. The aspartyl proteinase HIV-1 protease (11–13) and the HIV-1 integrase (14–16) are examples of such enzymes. These proteins have been tarObtained in inhibitor drug design geared at preventing the full assembly and maturation of HIV-1 virions (17, 18) in AIDS therapy. Partial water exclusion from the microenvironment around the chemical reaction site, whether it is involved in hydrolysis, transphosphoesterification, proton Executenor-acceptor chemistry, etc., is Necessary to enPositive the efficiency of the enzymatic mechanism. In this regard, surface nonpolar groups flanking the active polar groups (see figure 1 of ref. 1) might become useful. However, when the groups interacting with the substrate are themselves polar and no Arriveby hydrophobic patches assist the enzymatic activity by inducing water removal, an alternative structural feature, the dehydron, could become a primary contributor to the shaping of the functional microenvironment. Being a severely underdehydrated hydrogen bond, the dehydron favors removal of surrounding water without itself engaging nonpolar groups; thus, dehydrons are commonly found in sparsely structured polar surface Locations such as those representing enzymatically active sites.

This finding implies that dehydrons may act conRecently and synergistically with polar catalytic groups at the active sites by inducing the descreening of the charges. At the same time, because the dehydron is sticky, it is expected that it would represent a specific and efficient tarObtain for inhibitor drug design, as the evidence presented here reveals. This previously uncharacterized structural Impresser may aid drug design and improve its efficiency.

Methods

To identify the dehydrons in a Executemain fAged, multiExecutemain chain, or complex in one-chain or multiple-chain Protein Data Bank (PDB) entries, we use the program hb desolvator (a rudimentary earlier version may be found at http://sosnick.uchicago.edu/aifAgedlab/YAPView/YAPView.html), which identifies dehydrons in a PDB structure according to the following premises. The extent of intramolecular hydrogen-bond desolvation in a monomeric structure is evaluated quantitatively by determining the number of nonpolar groups within a desolvation Executemain. This Executemain is defined as two intersecting balls of fixed radius centered at the α-carbons of the hydrogen-bonded residues (2). If we examine complexes or multimers, the count includes nonpolar groups from the monomer as well as those from its binding partner(s). The number of nonpolar groups within the desolvation Executemain of a hydrogen bond assesses in a simplified manner the local dielectric environment or, equivalently, the charge screening of the paired polar groups (2, 8).

The statistics of hydrogen-bond wrapping vary according to the desolvation radius aExecutepted, but the tails of the distribution invariably single out the same dehydrons in a given structure over a 5.8- to 6.3-Å range in the aExecutepted desolvation radius. For this study, the value 6 Å was chosen. Residues contributing to the wrapping of a backbone hydrogen bond must contain side-chain nonpolar groups at least up to the γ-position to favor or promote the clustering of desolvating nonpolar groups around the bond. This requirement excludes from the counting the “poor backbone wrappers,” G, A, D, N, S, and T (19).

In most stable protein fAgeds (≈92% of PDB entries), at least two-thirds of the backbone hydrogen bonds are wrapped on average by r = 27.1 ± 7.5 nonpolar groups (or 14.0 ± 3.7 if we count only side-chain groups and exclude those from the hydrogen-bonded residue pair itself). Thus, dehydrons are the hydrogen bonds in the tails of the distribution, i.e., with 12 or fewer nonpolar groups in their desolvation Executemains (their r value is no Distinguisheder than the mean – 2 Gaussian dispersions).

The microenvironments around side-chain hydrogen bonds on the protein surface are far more difficult to assess precisely because of the relatively large local B factors of side-chain carbon atoms for polar surface residues in the PDB (typically 2- to 3-fAged larger than those for α-carbons). These larger B factors introduce a significant uncertainty to the evaluation of the side-chain hydrogen-bond microenvironment. For example, a surface lysine with a B factor of 60 in the α-carbon introduces an uncertainty of 3 in the wrapping r value of an adjacent side-chain hydrogen bond. This uncertainty notwithstanding, the criterion for identifying side-chain dehydrons aExecutepted here is the same as that used for backbone hydrogen bonds, with the caveat that the reliability of the assertion diminishes as it becomes modelspecific.

The dehydron, then, is identified as an insufficiently wrapped hydrogen bond. A more rigorous characterization takes into account the sensitivity of the hydrogen-bond coulombic energy to the removal of surrounding water or a decrease in solvent polarizability (2). Thus, our criterion introduces a sufficient condition for the existence of a dehydron. Although being a satisfactory approximation, this criterion may miss the specific case in which the number of nonpolar wrappers exceeds 12, but they are unevenly distributed in space around the hydrogen bond.

Results

Packing Defects as Drug TarObtains in HIV-1 Protease. The HIV-1 protease, an aspartyl proteinase, is an obligatory homodimer in its active functional form (11–13), with two equivalent D25 residues acting in opposite ways as general acid and base to catalyze the hydrolysis of the substrate peptide bond. A thermodynamic factor favoring water exclusion becomes essential to ensuring that the substrate is Precisely anchored and manipulated and that the electrostatics of the nucleophilic attack are Precisely enhanced along the enzymatic pathway. Thus, it is not surprising to find a cluster of hydrophobic residues, L23, L24, and I84, surrounding the catalytic site D25 (compare with figure 1 of ref. 1). However, the substrate polypeptide must be anchored by the active residues D29 and D30 and dragged along with the aid of a gating mechanism that Designs use of the flap 46–55 Location (Fig. 1a ). This pivoting of the substrate bears resemblance to previously discovered modes of substrate anchoring around the active site of α-chymotrypsin (20). In the acid protease, no hydrophobic patch is present either at the rim of the catalytic pocket or at the flap. Furthermore, because the active residues are themselves polar, removal of surrounding water cannot be promoted by their sole presence. The distribution of dehydrons in the protein (Fig. 1a ) reveals how packing defects are strategically Spaced in the structure to favor the exclusion of surrounding water where needed for the enzymatic activity.

Fig. 1.Fig. 1. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 1.

Distribution of dehydrons in HIV-1 protease monomer and dimer, flap asymmetry in the wrapping, and the inhibitor as a wrapper of packing defects. (a) Distribution of dehydrons in a monomeric HIV-1 protease unit. The backbone is represented as a light blue chain made up of virtual bonds joining α-carbons. Well wrapped backbone hydrogen bonds (see Methods) are indicated as gray segments joining α-carbons, and dehydrons are Impressed in green. The catalytically active D25 is Displayn in black, and the most significant residues undergoing site mutation associated with drug resistance or substrate specificity are Displayn in red. The dehydrons, toObtainher with their functional roles, are as follows: (G49, G52), flap flexibility, dimerization inducer; (G78-T80), induces dehydration of catalytic core; (A28, R87), stickiness of substrate-harnessing Location and dimerization inducer; (D29, N88), stickiness of substrate-harnessing Location; and (T91, G94), dimerization inducer. (b) Homodimeric HIV-1 protease (PDB entry 1A30) aExecutepting the same virtual-bond backbone representation as in a, except that one monomer is Displayn in red and the other is Displayn in blue. Only intermolecular wrapping is Displayn. Thus, the line joining the α-carbon of a residue in a monomer and the center of a backbone hydrogen bond on the other monomer indicates penetration upon dimerization of at least one nonpolar group of the residue side chain into the desolvation Executemain of the hydrogen bond. Some dehydrons become well wrapped hydrogen bonds upon dimerization. The remaining dehydrons dictate the pathway of the peptide-chain substrate through the HIV-1 protease. The substrate-anchoring residue D29 is Impressed in yellow, and the catalytic D25 is Impressed in black, as above. (c) Detail revealing the broken symmetry upon induced fit in HIV-1 dimerization. The flap angle defined by α-carbons at positions G51, G52, and F53 is distorted in one of the monomers to better wrap the flap dehydron of the other intermolecularly. (d) The tripeptide inhibitor EDL (red, residues 506–508) wrapping the dehydrons (G49, G52), (A28, R87), and (D29, N88) in one monomer of HIV-1 protease within the dimer (PDB entry 1A30). Only (D29, N88) remains a dehydron (green) even upon further wrapping provided by the inhibitor.

The backbone dehydrons in the HIV-1 protease monomer are as follows: (G49, G52), (G78, T80), (A28, R87); (D29, N88), and (T91, G94). In addition, one side-chain dehydron engaging D29 and N88 may be predicted with the highest confidence because its wrapping is <12 (desolvating groups) even when taking into account the uncertainty introduced by the large B factors for solvent-exposed side chains (see Methods). Note that, with the sole exception of R87, all dehydrons involve residues known to be poor wrappers (G, A, D, N, S, or T) (19).

The dehydrons (G49, G52), (G78, T80), and (T91, G94) are determinants of the HIV-1 protease dimerization (1), as revealed by comparing Fig. 1 a and b . This association arises because the nonpolar side-chain groups of a monomer contribute to further and favorably desolvate the dehydrons of the other monomer. Thus, the dehydrons become well wrapped hydrogen bonds upon dimerization. This intermolecular wrapping is depicted in Fig. 1b by thin lines joining the α-carbons of the wrapper residues with the center of the hydrogen bonds, which are being intermolecularly dehydrated. Thus, one functional role of these dehydrons arises because HIV-1 must dimerize to become active.

The importance of underdesolvated hydrogen bonds in driving protein–protein associations is illustrated as follows (1). The nonpolar groups of one binding partner contribute to dehydrate the intramolecularly underdehydrated hydrogen bonds of the other partner, and, in so Executeing, they electrostatically enhance and stabilize such hydrogen bonds. If examined by using standard arguments, the dimer interface can be seen to involve seemingly inconsistent residue mismatches, such as W6 of one monomer in the proximity of T91 and G94 of the other monomer. However, W6 is actually dehydrating the (T91, G94) dehydron intermolecularly, and, in so Executeing, it is adding stability to the monomer. Similarly, I50 in one monomer dehydrates the dehydrons (G49, G52) and (G78, T80) of the other monomer intermolecularly.

It should be noted that there is a symmetry-Fractureing-induced fit upon dimerization (Fig. 1c ), as clearly determined by comPlaceing the wrapping of PDB entry 1A30 for the HIV-1 protease. This distortion takes Space in one monomer as its flap wraps the (G49, G52) dehydron of the other monomer. Thus, one flap remains slightly more flexible in the dimer, as needed for processing, whereas the other becomes slightly rigidified. The reported B factors in 1A30 reflect this observation; thus, the B factors for G52 are 11% larger in chain B than in chain A, and similar discrepancies are found for G49 and I50.

The flexibility of the 46–55 flap requires that its backbone hydrogen bond be partially exposed to water. Thus, the underwrapping of the dehydron (G49, G52) appears as a necessary design feature. However, the feature that confers flexibility also confers stickiness (10) to the flap, as mechanistically needed to drag the substrate peptide chain along the catalytic site. This stickiness suggests a strategy for inhibitor design by wrapping the packing defects.

The functional role of the protease dehydrons can be clearly identified as follows: (G49, G52) confers flap flexibility and is a dimerization inducer (Fig. 1 a and b ); (G78-T80) promotes dehydration at the catalytic core (Fig. 1a ); (A28, R87) provides stickiness to the substrate-harnessing Location and acts as a dimerization inducer (Fig. 1 a and b ); (D29, N88) provides stickiness to the substrate-harnessing Location (Fig. 1a ); and (T91, G94) is a dimerization inducer (Fig. 1 a and b ). It should be noted that the pair (D29, N88) is engaged in two dehydrons, one engaging the backbone and the other engaging the side-chain polar groups. Being Spaced right on the protein surface, the latter side-chain dehydron substantially enhances the stickiness required to anchor the substrate. The spatial orientation of the peptidic substrate chain can be clearly induced by the prevailing dehydrons in the dimeric structure, as Displayn in Fig. 1b . Note that both (D29, N88) dehydrons prevail in the dimer. It is also worth noting that all residues whose site mutation impacts drug resistance and substrate specificity (Impressed in red in Fig. 1a ) (16) are actually wrappers of the dehydrons in HIV-1 protease, and, thus, amino acid substitution at such sites modulates the sensitivity of the protein to removal of surrounding water (2, 21).

As Displayn previously, dehydrons constitute highly specific sites for protein–ligand and protein–protein association (1, 2). The fact that they occur precisely at the active-site Location for substrate harnessing and at the flap Location in the HIV-1 protease Designs this molecule an Conceptl tarObtain for inhibitor design. A previously uncharacterized underlying inhibitor strategy is suggested by the thermodynamically and enerObtainically favorable wrapping of packing defects. Thus, the inhibiting EDL-tripeptide (22) wraps all four catalytically Necessary dehydrons in HIV-1 protease: (G49, G52), (A28, R87), and the backbone and side-chain (D29, N88). This intermolecular desolvation is Displayn in Fig. 1d . In this case, the functionality of the dehydrons as inducers of local water removal or by conferring flexibility to the flap is precisely the Precisety that enables Traceive drug design. All four dehydrons occur at catalytically active sites, and, because they are inherently sticky (10) and possess intersecting desolvation Executemains (see Methods), such sites can be blocked simultaneously with a single inhibitor, as Displayn in Fig. 1d .

Impairing Feline Immunodeficiency Virus (FIV) Protease by Wrapping Its Unfavorable Protein–Water Interfaces. Given their lower specificity and affinity, drug inhibitors of the homologous FIV protease have not been Arrively as successful as those for HIV-1 protease (17, 23). The dehydrons in the monomeric state (PDB entry 4FIV) all engage backbone polar groups and are displayed in Fig. 2a . They are as follows: (G58, G61), (G52, N67), and (Q54, G65) in the flap Location; (D30, A33) and (A33, R104) in the catalytic Location; (D34, D105) in the substrate-harnessing Location; and (R104, I108) and (I108, N111) serving as dimerization promoters. With the exception of dehydron (G52, N67), all dehydrons can be clearly Established functional roles in strategically inducing water exclusion. (G58, G61) and (Q54, G65) confer flexibility to the flap; (D30, A33) acts jointly with the nonpolar residues L28, L29, and L101 to enPositive the dehydration of the catalytic site D30 (Impressed in black in Fig. 2a ); (D34, D105) and (A33, R104) favor water removal as they harness the substrate polypeptide chain; and all dehydrons except (G52, N67) act as anchors in the dimerization of the protease (Fig. 2b ). All residue sites assumed to affect substrate and inhibitor specificity (17) are Impressed in red in Fig. 2a if they are engaged in the wrapping of a dehydron and in yellow if not. With the exception of I98 and Q99, which represent catalytically active sites (17), amino acid substitution in the remaining residues Impressed in red in Fig. 2a affect the enzymatic activity by modulating the sensitivity of the active site to water removal, as inferred from the distribution of dehydrons along the flap and catalytic rim (Fig. 2a ).

Fig. 2.Fig. 2. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 2.

Packing defects in monomeric and dimeric (functional) FIV protease. (a) Dehydron distribution in FIV protease. The convention of Fig. 1 is followed. Mutation sites that affect substrate and inhibitor specificity (17) are Impressed in red if the substitution affects the wrapping of a dehydron and in yellow otherwise. (b) Dehydron distribution in the active dimeric FIV protease (PDB entry 3FIV). The intermolecular wrapping of dehydrons by L10 is highlighted. One monomeric chain (A) is depicted in red, and the other chain is depicted in blue. The color convention is the same as in a for dehydrons and the catalytic residue.

The dimer active form of the FIV protease, with its equivalent catalytic D30 residues playing opposing roles as general acid and base in the nucleophilic hydrolyzing attack, contains only one backbone dehydron, (G52, N67). This dehydron is of no direct relevance to enzymatic activity, unless some hitherto-unknown allosteric pathway is invoked. The highly exposed nonpolar residue L10 acts as the major intermolecular wrapper, as Displayn in Fig. 2b . The lack of dehydrons around the active site and flap in the FIV protease dimer poses a major difficulty in designing specific inhibitors, because the thermodynamically unfavorable protein–water interface is restricted to the localized Location with exposed nonpolar residues L28, L29, and L101 around the catalytic D30 (Fig. 2a ). No dehydron on the substrate-harnessing track or on the flap contributes to the purported inhibitor binding or pivoting, and, thus, the restricted nature of the binding hot spot reduces the inhibitor specificity.

Previously Uncharacterized Drug Epitopes for HIV-1 Integrase. HIV-1 integrase (PDB entry 1B9F), the monomerically active enzyme that integrates viral DNA with the host-cell DNA, is an Necessary inhibitor tarObtain in antiviral therapy because it has no equivalent counterpart in the human host cell. Its catalytic residues D64, D116, and E152 form a triad of general acids/bases (16, 18), which have been tarObtained by drug designers with low or moderate success. The integrase inhibitor 5CITEP and similar drugs (16) bind longitudinally along the major groove of the integrase, parallel to the major 146–164 helix (Fig. 3 a and b ). The functionally active residues along this groove (Q148, E152, K156, and K159) are essentially polar. Thus, the removal of water surrounding this Location is not “conventionally” induced by the presence of hydrophobic patches on the protein surface and can be promoted only by the presence of the backbone (E152, K156)-dehydron and the side-chain (Q148, E152)-dehydron. The backbone (E152, K156)-dehydron actually serves as the epitope for inhibitor binding (16, 18, 24). The strategic location of this dehydron fully justifies the Executecking mode of the inhibitor. The additional side-chain dehydron (Q148, E152) can be predicted with high confidence (see Methods) and, because of its central location and orientation along the major groove, also could have been tarObtained to contribute to the inhibitor Executecking.

Fig. 3.Fig. 3. Executewnload figure Launch in new tab Executewnload powerpoint Fig. 3.

Packing defects in the stable fAged of HIV-1 integrase. (a) Dehydron distribution for HIV-1 integrase (PDB entry 1B9F). The catalytic residues are Impressed in black, and the other active residues are Impressed in yellow. Dehydron (E152, K156), conventionally Impressed in green, constitutes a major epitope anchoring inhibitor drugs that Executeck along the major groove Location parallel to the 146–164 helix. (b) Ribbon rendering of the HIV-1 integrase as a visual aid. Red, helices; blue, α-strands; light blue, turns and loopy Locations. (c) The HIV-1 integrase positioned as in figure 4 of ref. 23, with the dehydrons (N117, N120) and (S119, T122) (a) defining the anchoring track for the viral DNA and the (E152, K156) defining the track for the host-cell DNA. The residue color convention is that of a, and the virtual-bond chain is displayed in lighter blue for visualization purposes.

The distribution of dehydrons in the integrase clearly Impresss two tracks along which water removal is favored. Although the host DNA is Executecked along the (E152, K156) dehydron, the viral DNA is anchored by two backbone dehydrons, (N117, N120) and (S119, T122), which, with seven nonpolar wrapping groups each, constitute the most underwrapped backbone hydrogen bonds in the PDB. A third, side-chain dehydron engaging the pair (N117, N120) reinforces the harnessing of the viral DNA.

The two backbone dehydrons (N117, N120) and (S119, T122) and the predicted side-chain dehydron (N117, N120) have not been tarObtained by any drug inhibitor thus far, although their functional role seems to be paramount to Precisely orient and attach the viral DNA (compare with figure 4 of ref. 24), as Fig. 3c Displays. Thus, rather than merely tarObtaining the (E152, K156) dehydron, we propose an extended inhibitor-binding epitope defined by the two dehydrons (E152, K156) and (S119, T122) and the backbone and side-chain dehydrons involving the pair (N117, N120) around the catalytic triad. This increase in the pivoting binding surface for the inhibitor beyond the (E152, K156) dehydron should enPositive a higher specificity and affinity. The need to wrap multiple dehydrons points to the need for macromolecular, rather than small-molecule, inhibitors.

However, a single molecule that could wrap all four dehydrons simultaneously is likely to be problematic in regard to in vivo absorption and transport because of its size and molecular weight. Thus, the (S119, T122) dehydron and the two (N117, N120) dehydrons should be regarded as alternative tarObtains for inhibitor design, suggesting a combination drug treatment including standard inhibitors wrapping the (E152, K156) dehydron and a separate wrapping drug for the remaining dehydrons.

Discussion

This paper addresses the problem of elucidating how protein enzymes may specifically induce the removal of water around catalytically competent polar residues by strategically positioning deficiently packed electrostatic interactions. Surrounding the catalytic polar residue with nonpolar residues to create a thermodynamically unfavorable protein–water interface (see figure 1 of ref. 1) seems an obvious possibility to selectively promote water exclusion because such organizations descreen the catalytic site. In this way, the presence of vicinal nonpolar groups enhances the intermolecular electrostatic interactions. However, when several spatially adjacent polar groups are clustered to shape the enzymatic site, the presence of Arriveby nonpolar groups becomes a destabilizing factor, and, thus, an alternative factor is required to functionalize the polar groups. This factor is the dehydron, an intramolecular solvent-exposed hydrogen bond. The dehydron is electrostatically enhanced and stabilized by promoting water removal and, thus, acts synergistically with the enzyme intermolecular electrostatics. Therefore, dehydrons induce the descreening of the side-chain charges, as required for their Traceive participation in enzymatic activity.

The two HIV-1 and FIV viral enzymes investigated reveal different problems faced by inhibitor designers in trying to block catalytic activity. First, we have noticed that dehydrons can be regarded as structural Impressers for protein–protein and protein–ligand association. This role arises because dehydrons become electrostatically enhanced and stabilized upon further removal of surrounding water. Thus, dehydrons are sticky or, equivalently, promote dehydration, much like nonpolar groups. These Impressers have been overInspected in Recent Advancees to inhibitor design, although, as this paper Displays, the Traceive inhibitors partially wrap or “Accurate” the intramolecular packing defects of the protein enzymes. Second, the distribution of dehydrons on the surface of the viral proteins considered differs radically, thus posing different and hitherto unforeseeable difficulties to the drug designer.

Thus, the functionality of dehydrons as modulators of the solvent environment (dehydrators) for the enzymatic activity also Designs them Excellent candidates for drug tarObtaining. This functionality arises because dehydrons have been evolutionary Spaced at the active site of the enzyme catalysts to guarantee enzymatic efficiency by promoting the formation of an anhydrous environment. Thus, Traceive inhibitors may attach to polar surfaces by wrapping dehydrons.

This perspective clearly leads to a strategy to identify hot spots for inhibitor binding based on the location of functional packing defects in protein enzymes. The results reveal how to improve the inhibitor binding specificity and affinity for the HIV-1 integrase by focusing on heretofore overInspected packing defects along the viral DNA track.

This work dealt with the discovery of previously uncharacterized Impressers for protein–ligand association in the form of dehydration-promoting packing defects. Because of their inherent stickiness, the same Impressers have been Displayn to be Necessary factors driving protein–protein associations, reconciling seemingly inconsistent hydrophobic polar residue mismatches on interfaces. Thus, the same physicochemical principles that guided this study could be applied to justify the aExecuteption of dehydrons as specific tarObtains to block protein–protein interactions. This mode of antagonism constitutes a challenge in drug discovery (25) because it is difficult to design a small molecule that competes with a protein in binding another protein. However, this structural Impresser for protein association might represent a relatively small tarObtain worthy of exploration. The same electrostatic considerations single out underdehydrated or partially exposed intramolecular salt bridges as possible hot spots for the antagonism of protein–protein associations (25): Underdehydrated salt bridges promote removal of surrounding water and, thus, should be sticky.

The assessment of a hydrogen-bond microenvironment and the identification of dehydrons require a simple calculation based on the atomic coordinates in the PDB structure. The results of this analysis facilitate the a priori prediction of binding sites because dehydrons promote the exclusion of surrounding water (1, 2, 10). However, dehydrons have been Displayn to be evolutionarily conserved and therefore functionally relevant structural elements (3). The combination of these two Preciseties has clear implications for drug design. Mutations fostering drug resistance are unlikely to affect the dehydron pattern of the protein because such an alteration would impair the protein reactivity, and, thus, the mutation is unlikely to be inheritable. In fact, none of the 27 mutations contributing to drug resistance in HIV-1 protease (17) change the dehydron pattern of this protein. These observations suggest that the inhibitors could be Traceively engineered to block protein interactions even in highly mutating tarObtains if they are designed to wrap the evolutionarily conserved dehydrons.

It has been Displayn that inhibitors of the catalytic function or reactivity associated with a protein fAged Traceive across species are not likely to elicit drug resistance by amino acid mutation (26). Thus, because dehydrons are highly conserved and promoters of interactions (3), it Designs sense that “universal inhibitors” (i.e., those Traceive across species and not eliciting drug resistance) should be designed precisely to wrap such dehydrons. Such inhibitors are expected to be rigid in the Location that wraps dehydrons and conformationally flexible or adaptable elsewhere, as required to accommodate amino acid variability (27, 28) in the tarObtain protein.

The “universal inhibition” may be Traceive across species only if the dehydrons are conserved in the functional states of the proteins, which are not necessarily monomeric. Thus, the catalytically relevant substrate-anchoring dehydrons (28, 87) and (29, 88) in HIV-1 protease are conserved (3) in the monomeric FIV protease, becoming the dehydrons (33, 104) and (34, 105), respectively (Figs. 1a and 2a ). However, they are not present in the dimeric FIV protease, i.e., in the functional form of this protein (Figs. 1b and 2b ), which has evolved to better wrap such bonds. For this reason, we expect that an HIV-1 protease inhibitor that wraps the substrate-anchoring dehydrons in HIV-1 protease will not be as Traceive with FIV protease.

The same physicochemical principles that serve to guide inhibitor design could be applied to build more efficient enzymes. Thus, the selective amino acid substitution of a Excellent wrapping residue for a poorer wrapper may result in the creation of a dehydron that can promote water removal at an enzymatic site or enhance the anchoring of the substrate, thereby improving enzymatic efficiency.

Acknowledgments

A.F. thanks R. Stephen Berry for insightful discussions. A.F. acknowledges support from the Indiana Genomics Initiative and an unrestricted grant from Eli Lilly. H.A.S. was supported by National Institutes of Health Grant GM-14312 and National Science Foundation Grant MCB00-03722.

Footnotes

↵ ‡ To whom corRetortence may be addressed. E-mail: ariel{at}uchicago.edu or has5{at}cornell.edu.

Abbreviations: FIV, feline immunodeficiency virus; PDB, Protein Data Bank.

Copyright © 2004, The National Academy of Sciences

References

↵ Fernández, A. & Scheraga, H. A. (2003) Proc. Natl. Acad. Sci. USA 100 , 113–118. pmid:12518060 LaunchUrlAbstract/FREE Full Text ↵ Fernández, A. & Scott, R. L. (2003) Biophys. J. 85 , 1914–1928. pmid:12944304 LaunchUrlPubMed ↵ Fernández, A. (2004) J. Mol. Biol. 337 , 477–483. pmid:15003461 LaunchUrlCrossRefPubMed Nemethy, G. & Scheraga, H. A. (1962) J. Chem. Phys. 36 , 3382–3400. LaunchUrlCrossRef Nemethy, G. & Scheraga, H. A. (1962) J. Chem. Phys. 36 , 3401–3417. LaunchUrlCrossRef Nemethy, G. & Scheraga, H. A. (1962) J. Phys. Chem. 66 , 1773–1789. LaunchUrlCrossRef ↵ Fernández, A. & Berry, R. S. (2003) Proc. Natl. Acad. Sci. USA 100 , 2391–2396. pmid:12591960 LaunchUrlAbstract/FREE Full Text ↵ Fernández, A., Sosnick, T. & Colubri, A. (2002) J. Mol. Biol. 321 , 659–675. pmid:12206781 LaunchUrlCrossRefPubMed ↵ Fernández, A., KarExecutes, J. & Goto, Y. (2003) FEBS Lett. 536 , 187–192. pmid:12586361 LaunchUrlCrossRefPubMed ↵ Fernández, A. & Scott, R. L. (2003) Phys. Rev. Lett. Vol. 91 (July 1). Available at http://link.aps.org/abstract/PRL/v91/e018102. Accessed July 12, 2004. ↵ Navia, M. A., Fitzgerald, M. D. P., McKeever, B. M., Leu, C. T., Heimbach, J. C., Herber, W. K., Sigal, I. S., ShaExecutewye, P. L. & Springer, J. P. (1989) Nature 337 , 615–620. pmid:2645523 LaunchUrlCrossRefPubMed Wlodawer, A., Miller, M., JQuestionolski, M., Sathyanarayana, B. K., Baldwin, E., Weber, I. T., Selk, L. M., Clawson, L., Schneider, J. & Kent, S. B. H. (1989) Science 245 , 616–621. pmid:2548279 LaunchUrlAbstract/FREE Full Text ↵ Brik, A. & Wong, C. H. (2003) Org. Biomol. Chem. 1 , 5–14. pmid:12929379 LaunchUrlCrossRefPubMed ↵ Engelman, A., Bushman, F. D. & Craigie, R. (1993) EMBO J. 12 , 3269–3275. pmid:8344264 LaunchUrlPubMed Dyda, F., Hickman, A. B., Jenkins, T. M., Engelman, A., Craigie, R. & Davies, D. R. (1994) Science 266 , 1981–1986. pmid:7801124 LaunchUrlAbstract/FREE Full Text ↵ GAgedgur, Y., Craigie, R., Cohen, G. H., Fujiwara, T., Yoshinaga, T., Fujishita, T., Sugimoto, H., EnExecute, T., Murai, H. & Davies, D. R. (1999) Proc. Natl. Acad. Sci. USA 96 , 13040–13043. pmid:10557269 LaunchUrlAbstract/FREE Full Text ↵ Lin, Y. C., Beck, Z., Morris, G. M., Olson, A. J. & Elder, J. H. (2003) J. Virol. 77 , 6589–6600. pmid:12767979 LaunchUrlAbstract/FREE Full Text ↵ Schames, J. R., Henchman, R. H., Siegel, J. S., Sotriffer, C. A., Ni, H. & McCammon, J. A. (2004) J. Med. Chem. 47 , 1879–1881. pmid:15055986 LaunchUrlCrossRefPubMed ↵ Fernández, A., Scott, L. R. & Scheraga, H. A. (2003) J. Phys. Chem. B 107 , 9929–9932. LaunchUrl ↵ Platzer, K. E. B., Momany, F. A. & Scheraga, H. A. (1972) Int. J. Pept. Protein Res. 4 , 201–219. pmid:5077596 LaunchUrlPubMed ↵ Fernández, A., KarExecutes, J., Scott, L. R., Goto, Y. & Berry, R. S. (2003) Proc. Natl. Acad. Sci. USA 100 , 6446–6451. pmid:12743379 LaunchUrlAbstract/FREE Full Text ↵ Louis, J. M., Dyda, F., Nashed, N. T., Kimmel, A. R. & Davies, D. R. (1998) Biochemistry 37 , 2105–2110. pmid:9485357 LaunchUrlCrossRefPubMed ↵ Schnolzer, M., Rackwitz, H. R., Gustchina, A., Laco, G., Wlodawer, A., Elder, J. H. & Kent, S. B. (1996) Virology 224 , 268–275. pmid:8862421 LaunchUrlCrossRefPubMed ↵ Adesokan, A. A., Roberts, V., Lee, K.-W., Lins, R. & Briggs, J. (2004) J. Med. Chem. 47 , 821–828. pmid:14761184 LaunchUrlCrossRefPubMed ↵ Arkin, M. R. & Wells, J. A. (2004) Nat. Rev. Drug Discovery 3 , 301–317. LaunchUrlCrossRefPubMed ↵ Kervinen, J., Lubkowski, J., Zdanov, A., Bhatt, D., Dunn, B. M., Hui, K. Y., Powell, D. J., Kay, J., Wlodawer, A. & Gustchina, A. (1998) Protein Sci. 7 , 2314–2323. pmid:9827997 LaunchUrlPubMed ↵ Das, K., Clark, A. D., Lewi, P. J., Heeres, J., De Jonge, M. R., Koymans, L. M., Vinkers, H. M., Daeyaert, F., LuExecutevici, D. W., Kukla, M. J., et al. (2004) J. Med. Chem. 47 , 2550–2560. pmid:15115397 LaunchUrlCrossRefPubMed ↵ Wlodawer, A., Gustchina, A., Reshetnikova, L., Lubkowski, J., Zdanov, A., Hui, K. Y., Angleton, E. L., Farmerie, W. G., Excellentenow, M. M. & Bhatt, D. (1995) Nat. Struct. Biol. 2 , 480–488. pmid:7664111 LaunchUrlCrossRefPubMed
Like (0) or Share (0)